It's a big day for reports: there's a fantastic look at employer/health plan satisfaction with PBMs, too
And the 340B war of words escalates, but I'm not getting worked up until the legal briefs start flying
And Cigna/Evernorth/Express Scripts decides that the best way to make the FTC PBM report go away is to sue the snot out of the agency
Plus the implications of the sudden wave of subcutaneous meds for price controls, and CMS pushes back against the 'M3P' abbreviation that you like so much
Actually, it's not that simple, but that's the abbreviation we'll be using around here.
Plus a poll on how we should be referring to the Medicare Prescription Payment Plan. MPPP? M3P? Smoothing?
And there's a great JAMA paper on PBM consolidation out ... and a House hearing today where they'll talk about it
And the moneyline on the topic of 'Medicare' dominating tonight's debate? +150
And Chuck Schumer continues to list insulin prices as a policy priority
Plus a new report from AAM shows that PBMs are increasingly moving generic drugs off of generic-drug formulary tiers
And why 'M3P' is a candidate for abbreviation of the year
And Reuters finds that MFPs are still higher than OUS prices, which will be a theme for the month
